TMBIM4 and hepatocellular carcinoma: In contrast, inhibition of NRF2 expression markedly enhanced the anticancer activity of erastin and sorafenib in HCC cells.[83] In HCC cells, sorafenib treatment induced Sigma‐1 receptor (S1R) migration from the nucleus and upregulated the S1R protein expression; NRF2 inhibition notably increased the mRNA expression of S1R.